San Carlos, California, U.S., September 24, 2026
Glycomine, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to GLM101 for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), a serious and multisystem rare genetic disorder for which there are currently no approved disease-specific treatments. The designation was based on clinical evidence from Glycomine’s open-label Phase 2a study, including reported improvements in ataxia and other clinical measures after 24 weeks of GLM101 treatment. GLM101 is an investigational mannose-1-phosphate replacement therapy designed to address the underlying biochemical deficiency caused by reduced PMM2 enzyme activity. The FDA Breakthrough Therapy designation provides a framework for closer interaction between the company and the agency during drug development and review. Glycomine is currently evaluating GLM101 in the global Phase 2b POLAR study, with topline results from the randomized portion expected in the fourth quarter of 2026.
FDA Grants Breakthrough Therapy Designation
The FDA grants Breakthrough Therapy Designation to investigational medicines intended for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may provide substantial improvement over available therapies on a clinically significant endpoint. The designation is intended to facilitate more efficient drug development through increased interaction with the FDA. For Glycomine, the designation represents a regulatory milestone for GLM101 as the company continues to evaluate the therapy in patients with PMM2-CDG. The decision was supported by findings from the company’s Phase 2a clinical study, where Glycomine reported improvements in ataxia and other clinical measures after 24 weeks of treatment. The designation does not constitute FDA approval, and GLM101 remains an investigational therapy requiring additional clinical evaluation.
GLM101 Targets Underlying PMM2-CDG Deficiency
PMM2-CDG is caused by mutations in the PMM2 gene, which result in reduced activity of the phosphomannomutase 2 enzyme. PMM2 normally converts mannose-6-phosphate into mannose-1-phosphate, an essential substrate in the glycosylation pathway. Reduced availability of mannose-1-phosphate disrupts N-glycosylation and can affect the structure and function of proteins throughout the body. The disorder can therefore produce a broad range of neurological, developmental and multisystem manifestations. Glycomine designed GLM101 to deliver mannose-1-phosphate directly into cells, with the goal of bypassing the PMM2 enzyme deficiency and restoring pathway function. The company describes PMM2-CDG as the most prevalent congenital disorder of glycosylation, with an estimated birth incidence of approximately one in 30,000 to one in 40,000 in Europe and the United States.
Advertisement
Phase 2b POLAR Study Advances Clinical Development
GLM101 is currently being evaluated in the global POLAR Phase 2b clinical study, a randomized, double-blind and placebo-controlled trial involving pediatric and adult patients with PMM2-CDG. According to Glycomine, the study enrolled 43 patients across 15 sites in the United States, United Kingdom and Europe. The trial is designed to generate additional information on the safety and efficacy of GLM101 in people living with the rare disorder. Glycomine expects to report topline results from the randomized portion of POLAR in the fourth quarter of 2026. Following the randomized portion, participants may receive GLM101 through Week 48, allowing the company to collect additional information concerning longer-term safety and durability of treatment response, including data from participants who transition from placebo to active treatment.
The FDA designation adds regulatory momentum to Glycomine’s development program as the company prepares for the next clinical readout of GLM101. The therapy has previously received Orphan Drug Designation in the United States and European Union, as well as U.S. Rare Pediatric Disease and Fast Track designations. However, these regulatory designations do not establish efficacy or approval. The upcoming POLAR data will provide additional clinical evidence that can help determine the future development pathway for GLM101. For the PMM2-CDG community, continued clinical research is focused on determining whether replacing the deficient metabolic substrate can address disease mechanisms and produce meaningful clinical benefits. Glycomine’s latest FDA milestone therefore represents an important development in the company’s rare-disease drug development program, while further clinical evaluation remains necessary to establish the therapy’s safety and effectiveness.
Source: Glycomine press release
